94 related articles for article (PubMed ID: 7513143)
21. Lack of synergy between cisplatin and cytarabine against ovarian carcinoma in vitro.
Howell SB; Gill S
Cancer Treat Rep; 1986 Mar; 70(3):409-10. PubMed ID: 3955553
[TBL] [Abstract][Full Text] [Related]
22. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
23. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
24. Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells.
Yunos NM; Beale P; Yu JQ; Huq F
Anticancer Res; 2011 Apr; 31(4):1131-40. PubMed ID: 21508356
[TBL] [Abstract][Full Text] [Related]
25. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
Uslu R; Jewett A; Bonavida B
Gynecol Oncol; 1996 Aug; 62(2):282-91. PubMed ID: 8751562
[TBL] [Abstract][Full Text] [Related]
26. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Br J Cancer; 1994 Sep; 70(3):449-52. PubMed ID: 8080729
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
Deqnah N; Yu JQ; Beale P; Fisher K; Huq F
Anticancer Res; 2012 Jan; 32(1):135-40. PubMed ID: 22213298
[TBL] [Abstract][Full Text] [Related]
29. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
30. Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell lines.
Marverti G; Ligabue A; Guerrieri D; Paglietti G; Piras S; Costi MP; Farina D; Frassineti C; Monti MG; Moruzzi MS
Gynecol Oncol; 2010 May; 117(2):202-10. PubMed ID: 20031193
[TBL] [Abstract][Full Text] [Related]
31. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
[TBL] [Abstract][Full Text] [Related]
32. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
33. Enhanced sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to the combination of cisplatin and synthetic isothiocyanate ethyl 4-isothiocyanatobutanoate.
Bodo J; Chovancova J; Hunakova L; Sedlak J
Neoplasma; 2005; 52(6):510-6. PubMed ID: 16284698
[TBL] [Abstract][Full Text] [Related]
34. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
35. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
Taylor-Harding B; Orsulic S; Karlan BY; Li AJ
Gynecol Oncol; 2010 Dec; 119(3):549-56. PubMed ID: 20837358
[TBL] [Abstract][Full Text] [Related]
36. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
[TBL] [Abstract][Full Text] [Related]
37. Comparative evaluation of small-molecule chemosensitizers in reversal of cisplatin resistance in ovarian cancer cells.
Yellepeddi VK; Vangara KK; Kumar A; Palakurthi S
Anticancer Res; 2012 Sep; 32(9):3651-8. PubMed ID: 22993302
[TBL] [Abstract][Full Text] [Related]
38. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro.
Jekunen AP; Christen RD; Shalinsky DR; Howell SB
Br J Cancer; 1994 Feb; 69(2):299-306. PubMed ID: 7905279
[TBL] [Abstract][Full Text] [Related]
39. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Cancer Res; 1993 Apr; 53(7):1571-6. PubMed ID: 8453625
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and activity of a trinuclear platinum complex: [{trans-PtCl(NH3)2}2mu-{trans-Pt(3-hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in ovarian cancer cell lines.
Tayyem H; Huq F; Yu JQ; Beale P; Fisher K
ChemMedChem; 2008 Jan; 3(1):145-51. PubMed ID: 17963210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
